RESUMEN

BACKGROUND: Systemic lupus erythematosus (SLE) often mimics symptoms of other diseases, and the interval between symptom onset and diagnosis may be long in some of these patients. Aims: To describe the characteristics associated with the time to SLE diagnosis and its impact on damage accrual and mortality in patients with SLE from a Latin American inception cohort. METHODS: Patients were from a multi-ethnic, multi-national Latin-American SLE inception cohort. All participating centers had specialized lupus clinics. Socio-demographic, clinical/laboratory, disease activity, damage, and mortality between those with a longer and a shorter time to diagnosis were compared using descriptive statistical tests. Multivariable Cox regression models with damage accrual and mortality as the end points were performed, adjusting for age at SLE diagnosis, gender, ethnicity, level of education, and highest dose of prednisone for damage accrual, plus highest dose of prednisone, baseline SLEDAI, and baseline SDI for mortality. RESULTS: Of the 1437 included in these analyses, the median time to diagnosis was 6.0 months (Q1-Q3 2.4-16.2); in 721 (50.2%) the time to diagnosis was longer than 6 months. Patients whose diagnosis took longer than 6 months were more frequently female, older at diagnosis, of Mestizo ethnicity, not having medical insurance, and having "non-classic" SLE symptoms. Longer time to diagnosis had no impact on either damage accrual (HR 1.09, 95% CI 0.93-1.28, p = 0.300) or mortality (HR 1.37, 95% CI 0.88-2.12, p = 0.200). CONCLUSIONS: In this inception cohort, a maximum time of 24 months with a median of 6 months to SLE diagnosis had no apparent negative impact on disease outcomes (damage accrual and mortality).

Asunto(s)

RESUMEN

The new demands for sustainable operation in the chemical industry due to increasing environmental regulations and agreements have generated the need to adapt existing processes to more intelligent production. The plastics sector is in a complex position due to its contribution to economic development and the climate crisis. Therefore, environmental assessment has become an important tool due to the benefits it provides by quantifying the environmental performance of processes, allowing it to balance operational and environmental needs. Polyvinyl chloride (PVC) is one of the most globally used polymers thanks to its resistance, flexibility, and cost-effectiveness. The polymer is synthetized by suspension polymerization, which is characterized by high productivity and controllability. However, it presents problems associated with intensive energy consumption and the emission of toxic substances and greenhouse gases. Therefore, an environmental assessment of the suspension PVC production process was performed using the waste reduction algorithm (WAR). The potential environmental impact (PEI) was quantified using the generation rate and the output velocity for four cases and three different fuels. It was found that the process transforms raw materials with high impacts, such as VCM, into substances with lower PEI, such as PVC. However, the process has a high generation of PEI due to the effects of energy consumption (-2860, -2410, 3020, and 3410 for cases 1-4, respectively). The evaluation of the toxicological impacts shows that the ATP category is the only one that presents a positive generation value (75 PEI/day); the product contributes to the formation and emission of impacts. The atmospheric categories showed that the energy consumption of the process is the most critical aspect with a contribution of 91% of the total impacts emitted. The AP and GWP categories presented the highest values. It was determined that the most suitable fuel is natural gas; it has lower impacts than liquid and solid fuels (coal). Additionally, it can be concluded that the PVC production process by suspension is environmentally acceptable compared to the polyethylene or polypropylene processes, with output impacts 228 and 2561 times lower, respectively.

Asunto(s)

RESUMEN

With the objective of evaluating the quality parameters of raw milk in Ecuador between 2010 and 2020, a systematic review and meta-analysis of 73 studies on raw milk produced in different regions of Ecuador was performed. Under the random effects model, effect size and heterogeneity were determined vs. climatic region both among analyses and studies, with Cochran's Q, I2 and Tau (π) statistics. For all the variables, it was observed that there was great heterogeneity (I2 > 90%) among the studies; additionally, it was found that climatic region had an influence only among the variables arsenic, mercury, pH and total solids, and it was greater in the coastal region than the Inter-Andean region. The mean values of the physicochemical characteristics of the milk (titratable acidity, ash, cryoscopy, fat, lactose, pH, protein, non-fat solids and total solids) in the great majority of these studies were within the range allowed by Ecuadorian regulations. As for the hygienic quality of raw milk (total bacterial count, somatic cell count and presence of reductase), although the mean values were within those determined by local legislation, it should be noted that the range established by Ecuadorian regulations is relatively much higher compared to other regulations, which possibly means that there is a high presence of bacteria and somatic cells in raw milk. Finally, the presence of several adulterants (added water) and contaminants (AFM1, antibiotics and heavy metals) was confirmed in the milk, in addition to other substances such as eprinomectin, zearalenone and ptaquilosides, whose presence can be very dangerous, because they can be hepatotoxic, immunotoxic and even carcinogenic. In conclusion, there is great variability among the studies reviewed, with the physicochemical characteristics being the most compliant with Ecuadorian legislation; the hygienic characteristics, adulterants and contaminants of raw milk require greater attention by producers and local authorities, so that they do not harm the health of consumers and the profitability of producers in Ecuador.

RESUMEN

Mobile applications (Apps) may become effective aids in health care. Health Apps could reduce barriers such as access and costs and could be used to monitor symptoms, behaviors and even treatments. There is more evidence of their usefulness in nutrition, cardiovascular and mental health. Despite this, its current use is predominantly for information purposes. Healthcare App quality evaluation should consider both clinical and technological aspects since the evidence on its clinical effectiveness is still incipient and they have associated risks. In Chile, the use of mobile technology and Apps is increasing, but there are no regulations for their use. There are few national institutions oriented to the creation and development of Apps for healthcare, highlighting the Digital Transformation Committee, part of the Corporation for the Promotion of Production (CORFO) and the National Center for Health Information Systems (CENS). General recommendations for healthcare App development and use have been established. In this process, it would be beneficial to include actors involved in care. Given the progress of healthcare Apps worldwide and nationally, it is important that health professionals develop digital skills to maximize the potential benefit of these technologies.

Asunto(s)

RESUMEN

Mobile applications (Apps) may become effective aids in health care. Health Apps could reduce barriers such as access and costs and could be used to monitor symptoms, behaviors and even treatments. There is more evidence of their usefulness in nutrition, cardiovascular and mental health. Despite this, its current use is predominantly for information purposes. Healthcare App quality evaluation should consider both clinical and technological aspects since the evidence on its clinical effectiveness is still incipient and they have associated risks. In Chile, the use of mobile technology and Apps is increasing, but there are no regulations for their use. There are few national institutions oriented to the creation and development of Apps for healthcare, highlighting the Digital Transformation Committee, part of the Corporation for the Promotion of Production (CORFO) and the National Center for Health Information Systems (CENS). General recommendations for healthcare App development and use have been established. In this process, it would be beneficial to include actors involved in care. Given the progress of healthcare Apps worldwide and nationally, it is important that health professionals develop digital skills to maximize the potential benefit of these technologies.

Asunto(s)

RESUMEN

AIM: To validate the new classification criteria for antineutrophil cytoplasmic antibody-associated vasculitis in a real-life Peruvian cohort of antineutrophil cytoplasmic antibody-associated vasculitis patients. METHODS: We reviewed medical records from a Peruvian tertiary care center from January 1990 to December 2019. Antineutrophil cytoplasmic antibody-associated vasculitis was diagnosed based on the 1990 American College of Rheumatology (ACR) criteria, the 2012 Chapel Hill Consensus Conference definitions, the European Medicines Agency (EMEA) algorithm, and the clinical acumen of the treating rheumatologists. We classified all patients using the "former criteria" (the 1990 ACR criteria for granulomatosis with polyangiitis [GPA] and eosinophilic GPA [EGPA] and the 1994 Chapel Hill Consensus Conference definition for microscopic polyangiitis [MPA]), the EMEA algorithm, and the "new criteria" (the 2017 ACR/European League Against Rheumatism Provisional Criteria). The level of agreement (using Cohen κ) was calculated using the clinical diagnosis as the criterion standard. RESULTS: We identified 212 patients, 12 of whom were excluded. One hundred fifty-four (77%) had MPA, 41 (20.5%) GPA, and 5 (2.5%) EGPA. The new criteria performed well for MPA (κ = 0.713) and EGPA (κ = 0.659), whereas the EMEA algorithm performed well for GPA (κ = 0.938). In the overall population, the new criteria showed better agreement (κ = 0.653) than the EMEA algorithm (κ = 0.506) and the former criteria (κ = 0.305). CONCLUSIONS: The 2017 ACR/European League Against Rheumatism Provisional Criteria showed better agreement for the clinical diagnosis of all the patients overall and had the best performance for MPA and EGPA. The EMEA algorithm had the best performance for GPA.

Asunto(s)

RESUMEN

AIM: The aim of this study was to identify the demographic and clinical features of patients with ANCA-associated vasculitides (AAVs) in a Peruvian tertiary referral hospital. METHODS: Medical records of patients with AAV according to classification criteria or diagnosed by an experienced rheumatologist, and covering the period between January 1990 and December 2019, were reviewed. Granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), eosinophilic granulomatosis with polyangiitis (EGPA), and renal-limited vasculitis (RLV) were included. Demographic factors (age at diagnosis, sex), disease duration, clinical manifestations (per organ involvement), creatinine level at diagnosis (milligram per deciliter), ANCA status, diagnosis, 2009 Five Factor Score, disease categorization, and treatment were recorded. RESULTS: Two hundred twelve patients were included. Their female-to-male ratio was 1.9:1 (139 [65.6%]/73 [34.4%]), and their mean (SD) age at diagnosis was 59.2 (12.5) years. One hundred fifty-eight patients (74.5%) had MPA, 42 (19.8%) GPA, 7 (3.3%) RLV, and 5 (2.4%) EGPA. Neurological, lung, and renal involvements were the most frequently affected systems. Myeloperoxidase preferentially occurred in MPA (82.5%), whereas proteinase 3 did occur in GPA (79.5%). Microscopic polyangiitis patients were older (61.1 [11.5] years). Female sex predominated in MPA and RLV (2.4:1 and 6:1, respectively), but the opposite was the case for EGPA (1:4). Ear-nose-throat and ocular involvement were more frequent in GPA (both p's < 0.001), and neurological and cardiovascular involvement were more frequent in EGPA (p < 0.001 and p = 0.002, respectively). CONCLUSIONS: This is one of the largest series of AAV patients in Latin America. Overall, female sex predominated. Microscopic polyangiitis was the most frequent AAV, and myeloperoxidase-ANCA was the most frequent antibody in Peruvian AAV population.

Asunto(s)

RESUMEN

AIM: The aim of this study was to identify demographic and clinical risk factors for mortality in patients with antineutrophil cytoplasmic antibodies-associated vasculitides (AAVs) in a Peruvian tertiary referral hospital. METHODS: Medical records of patients with AAV according to classification criteria or diagnosed by an experienced rheumatologist, covering the period between January 1990 and December 2018, were reviewed. Granulomatosis with polyangiitis, microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis, and renal-limited vasculitis were included. Potential predictors of mortality were demographic factors, clinical manifestations, antineutrophil cytoplasmic antibodies status, diagnosis, disease categorization, the 2009 Five Factor Score (FFS), and treatment. Cox regression models were used to determine the risk factors for mortality. Univariable and multivariable analyses using a backward selection method were performed. RESULTS: One hundred ninety-six patients were included; female-to-male ratio was 2:1. The median (interquartile range) age at diagnosis and follow-up were 60.0 (51.0-68.0) and 4.8 (1.3-11.6) years, respectively. One hundred forty-eight patients (75.5%) had microscopic polyangiitis, 37 (18.9%) granulomatosis with polyangiitis, 5 (2.6%) eosinophilic granulomatosis with polyangiitis, and 6 (3.0%) renal-limited vasculitis. Overall survival rates at 1, 5, and 10 years were 83.4%, 68.2%, and 51.7%, respectively. Ocular involvement was protective (hazards ratio [HR], 0.36; 95% confidence interval [CI], 0.17-0.74; p = 0.006), whereas renal (HR, 2.09; 95% CI, 1.33-3.28; p = 0.001) and lung involvement (HR, 2.07; 95% CI, 1.31-3.28; p = 0.002) and the 2009 FFSs were predictive of mortality (2009 FFS = 1: HR, 2.46; 95% CI, 1.50-4.04; p < 0.001; 2009 FFS = 2: HR, 3.07; 95% CI, 1.54-6.10; p = 0.001; 2009 FFS = 3: HR, 13.29; 95% CI, 3.69-47.88; p < 0.001). CONCLUSIONS: Ocular involvement was protective, whereas 2009 FFS ≥ 1 and renal and lung involvement were predictive factors of mortality in Peruvian AAV patients.

Asunto(s)

RESUMEN

SARS-CoV-2 pandemic generated a profound impact on people's health, emphasizing the relevance of healthy lifestyles. Recommendations on how to maintain adequate physical activity, diet, sleep and social connection have been issued. However, it is worth expanding our look to other possible elements related to lifestyles such as the relationship with technology, nature, pets and music. These areas should be included in the assessment and intervention from this perspective. To achieve changes, the values, beliefs, intentions, motivations, risk/benefit balances, capacity for self-regulation, previous history of changes and the person's sense of competence in relation to the possible changes that are being suggested, should be assessed. Individualized and contextualized suggestions that increase the intention of change should be made, avoiding confrontation and generalizations. Although there are still areas of uncertainty in this approach, particularly in relation to dosage and mechanisms of action, its development should be encouraged, given its great potential in terms of cost-effectiveness.

Asunto(s)

Asunto(s)

RESUMEN

OBJECTIVES: This study aimed to compare the clinical features, damage accrual, and survival of patients with familial and sporadic systemic lupus erythematosus (SLE). METHODS: A multi-ethnic, multinational Latin American SLE cohort was studied. Familial lupus was defined as patients with a first-degree SLE relative; these relatives were interviewed in person or by telephone. Clinical variables, disease activity, damage, and mortality were compared. Odds ratios (OR) and 95% confidence intervals (CI) were estimated. Hazard ratios (HR) were calculated using Cox proportional hazard adjusted for potential confounders for time to damage and mortality. RESULTS: A total of 66 (5.6%) patients had familial lupus, and 1110 (94.4%) had sporadic lupus. Both groups were predominantly female, of comparable age, and of similar ethnic distribution. Discoid lupus (OR = 1.97; 95% CI 1.08-3.60) and neurologic disorder (OR = 1.65; 95% CI 1.00-2.73) were significantly associated with familial SLE; pericarditis was negatively associated (OR = 0.35; 95% CI 0.14-0.87). The SLE Disease Activity Index and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI) were similar in both groups, although the neuropsychiatric (45.4% vs. 33.5%; p = 0.04) and musculoskeletal (6.1% vs. 1.9%; p = 0.02) domains of the SDI were more frequent in familial lupus. They were not retained in the Cox models (by domains). Familial lupus was not significantly associated with damage accrual (HR = 0.69; 95% CI 0.30-1.55) or mortality (HR = 1.23; 95% CI 0.26-4.81). CONCLUSION: Familial SLE is not characterized by a more severe form of disease than sporadic lupus. We also observed that familial SLE has a higher frequency of discoid lupus and neurologic manifestations and a lower frequency of pericarditis.

Asunto(s)

Asunto(s)

RESUMEN

SARS-CoV-2 pandemic generated a profound impact on people's health, emphasizing the relevance of healthy lifestyles. Recommendations on how to maintain adequate physical activity, diet, sleep and social connection have been issued. However, it is worth expanding our look to other possible elements related to lifestyles such as the relationship with technology, nature, pets and music. These areas should be included in the assessment and intervention from this perspective. To achieve changes, the values, beliefs, intentions, motivations, risk/benefit balances, capacity for self-regulation, previous history of changes and the person's sense of competence in relation to the possible changes that are being suggested, should be assessed. Individualized and contextualized suggestions that increase the intention of change should be made, avoiding confrontation and generalizations. Although there are still areas of uncertainty in this approach, particularly in relation to dosage and mechanisms of action, its development should be encouraged, given its great potential in terms of cost-effectiveness.

Asunto(s)

RESUMEN

Peruvians currently preserve in their DNA the history of 2.5 million years of human evolution and 150,000 years of migration from Africa to Peru or the Americas. The development of Genetics and Genomics in the clinical and academic field is shown in this review.

Asunto(s)

RESUMEN

Objetivos: Estimar el efecto de los antimaláricos (AM) sobre los diferentes dominios del índice de daño SLICC (SDI). Métodos: Se estudiaron pacientes con diagnóstico clínico reciente (≤2 años) de lupus eritematoso sistémico (LES) de la cohorte GLADEL. Variable de estudio: aumento en los dominios del SDI desde el ingreso a la cohorte. Variables independientes: características sociodemográficas, clínicas, laboratorio y tratamientos. El efecto de los AM, como variable dependiente del tiempo, sobre los dominios más frecuentes del SDI (ajustado por factores de confusión) fue examinado con un modelo de regresión de Cox multivariado. Resultados: De 1466 pacientes estudiados, 1049 (72%) recibieron AM con un tiempo medio de exposición de 30 meses (Q1-Q3: 11-57) y 665 pacientes (45%) presentaron daño durante un seguimiento medio de 24 meses (Q1-Q3: 8-55); 301 eventos fueron cutáneos, 208 renales, 149 neuropsiquiátricos, 98 musculoesqueléticos, 88 cardiovasculares y 230 otros. Después de ajustar por factores de confusión, el uso de AM se asoció a un menor riesgo de daño renal (HR 0,652; IC 95%: 0,472-0,901) y en el límite de la significancia estadística (HR 0,701, IC 95%: 0,481-1,024) para el dominio neuropsiquiátrico. Conclusión: En GLADEL, el uso de AM se asoció independientemente a un menor riesgo de daño acumulado renal.

Objective: To assess the effects of antimalarials (AM) over the items of the SLICC Damage Index (SDI). Methods: Patients with recent (≤2 years) diagnosis of systemic lupus erythematosus (SLE) from the GLADEL cohort were studied. End-point: increase in items SDI since cohort entry. Independent variables (socio-demographic, clinical, laboratory and treatment) were included. The effect of AM as a time dependent variable on most frequent SDI items (adjusting for potential confounders) was examined with a multivariable Cox regression model. Results: Of the 1466 patients included in this analysis, 1049 (72%) received AM with a median exposure time of 30 months (Q1-Q3: 11-57). Damage occurred in 665 (45%) patients during a median follow-up time of 24 months (Q1-Q3: 8-55). There were 301 integument, 208 renal, 149 neuropsychiatric, 98 musculoskeletal, 88 cardiovascular and 230 others less frequently represented damages. After adjusting for potential confounders at any time during follow-up, a lower risk of renal damage (HR 0.652; 95% CI: 0.472-0.901) and borderline for neuropsychiatric damage (HR 0.701, 95% CI: 0.481-1.024) was found. Conclusion: In the GLADEL cohort, after adjustment for possible confounding factors, AM were independently associated with a reduced risk of renal damage accrual.

Asunto(s)

RESUMEN

Systemic lupus erythematosus (SLE), a complex and heterogeneous autoimmune disease, represents a significant challenge for both diagnosis and treatment. Patients with SLE in Latin America face special problems that should be considered when therapeutic guidelines are developed. The objective of the study is to develop clinical practice guidelines for Latin American patients with lupus. Two independent teams (rheumatologists with experience in lupus management and methodologists) had an initial meeting in Panama City, Panama, in April 2016. They selected a list of questions for the clinical problems most commonly seen in Latin American patients with SLE. These were addressed with the best available evidence and summarised in a standardised format following the Grading of Recommendations Assessment, Development and Evaluation approach. All preliminary findings were discussed in a second face-to-face meeting in Washington, DC, in November 2016. As a result, nine organ/system sections are presented with the main findings; an 'overarching' treatment approach was added. Special emphasis was made on regional implementation issues. Best pharmacologic options were examined for musculoskeletal, mucocutaneous, kidney, cardiac, pulmonary, neuropsychiatric, haematological manifestations and the antiphospholipid syndrome. The roles of main therapeutic options (ie, glucocorticoids, antimalarials, immunosuppressant agents, therapeutic plasma exchange, belimumab, rituximab, abatacept, low-dose aspirin and anticoagulants) were summarised in each section. In all cases, benefits and harms, certainty of the evidence, values and preferences, feasibility, acceptability and equity issues were considered to produce a recommendation with special focus on ethnic and socioeconomic aspects. Guidelines for Latin American patients with lupus have been developed and could be used in similar settings.

Asunto(s)

RESUMEN

OBJECTIVE: To define whether Amerindian genetic ancestry correlates with clinical and therapeutic variables in admixed individuals with rheumatoid arthritis (RA) from Latin America. METHODS: Patients with RA (n = 1347) and healthy controls (n = 1012) from Argentina, Mexico, Chile, and Peru were included. Samples were genotyped for the Immunochip v1 using the Illumina platform. Clinical data were obtained through interviews or the clinical history. RESULTS: Percentage of Amerindian ancestry was comparable between cases and controls. Morning stiffness (p < 0.0001, OR 0.05), rheumatoid factor (RF; p < 0.0001, OR 0.22), radiographic changes (p < 0.0001, OR 0.05), and higher number of criteria were associated with lower Amerindian ancestry after Bonferroni correction. Higher Amerindian ancestry correlated only with weight loss (pBonferroni < 0.0001, OR 2.85). Increased Amerindian ancestry correlated with higher doses of azathioprine (p < 0.0001, OR 163.6) and sulfasalazine (p < 0.0001, OR 48.6), and inversely with methotrexate (p = 0.001, OR 0.35), leflunomide (p = 0.001, OR 0.16), and nonsteroidal antiinflammatory drugs (pBonferroni = 0.001, OR 0.37). Only the presence of RF and weight loss were modified after confounders adjustment. CONCLUSION: Amerindian ancestry protects against most major clinical criteria of RA, but regarding the association of RF with increased European ancestry, age, sex, and smoking are modifiers. Ancestry also correlates with the therapeutic profiles.

Asunto(s)

RESUMEN

La osteoporosis es la enfermedad ósea más común en el mundo globalizado. Produce un alto impacto en el costo de la Salud Pública debido al incremento en forma progresiva en el correr del tiempo de vida del número de personas que la padecen, originada entre otros factores por la mayor expectativa de vida poblacional y disponer de nuevos procedimientos de diagnóstico, los que han conseguido gran penetración en las atenciones de salud. Las fracturas óseas son la principal consecuencia de esta enfermedad, las que originan dolor crónico, discapacidad y pérdida de la calidad de vida, pudiendo llevar inclusive a la muerte. Existen guías clínicas internacionales vigentes que se basan en evidencias de estudios clínicos aleatorizados y que dan pautas para el tratamiento de la osteoporosis y en especial de la forma posmenopáusica, ofreciendo tanto acciones farmacológicas como no farmacológicas. A raíz de resultados de estudios de seguimiento en gran número de pacientes, se discute en la actualidad aspectos de soporte terapéuticos tradicionales, como el uso y dosis de suplementos de calcio, sosteniéndose que en los que tienen una dieta adecuada de calcio existe un aparente no beneficio en su ingesta y es posible que un grupo de ellos puedan desarrollar eventos adversos como complicaciones, tales como constipación crónica, diverticulitis, litiasis renal o enfermedades cardiovasculares. Del mismo modo se reportan estudios que plantean la sugerencia de un uso con tiempo límite de bifosfonatos, sucediendo además de la pérdida de eficacia, la posibilidad de desarrollar eventos adversos como fracturas femorales atípicas y osteonecrosis de mandíbula. Este último evento adverso también es descrito con el uso de denosumab. O, por otro lado, en los que reciben teriperatida existe la infrecuente posibilidad de desarrollar neoplasias como el osteosarcoma, por lo que la recomendación es que su uso no debe superar los dos años. Finalmente, a raíz de las investigaciones sobre las concentraciones séricas de la vitamina D y su relación con los síntomas y signos que pueden dar su deficiencia, en las personas, y los posibles beneficios con acciones sobre la autoinmunidad, algunas neoplasias y una leve mejora de la masa ósea, da pie a sostener que el suplemento de vitamina D3 debe ser una parte importante en la terapia.

Osteoporosis is the most common bone disease in the globalized world, with high impact on health care costs due to progressive increase in life expectancy and the existence of new diagnostic procedures. Bone fractures are the main consequence of this disease, which cause chronic pain, disability and loss of quality of life, and can even lead to death. Existing international clinical guidelines based on evidence from randomized trials give standards for the treatment of osteoporosis, especially its post-menopausal form, offering both pharmacological and non-pharmacological actions. Based on results from follow-up studies in a large number of patients, we currently discuss aspects of traditional therapeutic support, such as the use and dosage of calcium supplements. It is proposed that there may exist an apparent non-benefit from its intake among those with an adequate level of dietary calcium; it is possible that some of them may develop adverse events such as chronic constipation, diverticulitis, kidney stones or cardiovascular disease. Similarly, some studies suggest to use biphosphonates for a limited period of time, which associates with loss of efficiency and the possibility of adverse events, such as atypical femoral fractures and osteonecrosis of the jaw bone. This last adverse event is also described with the use of denosumab. What is more, among those who receive teriperatide there exists the infrequent possibility of developing neoplasms such as osteosarcoma, so that the recommendation is that its use cannot exceed 2 years. Finally, as a result of research on serum concentrations of vitamin D and their relationship with signs and symptoms that may present in its deficiency, as well as the possible benefits from vitamin D on autoimmunity, some neoplasms and a mild improvement in bone mass, we can affirm that the supplementation with vitamin D3 must be an important part in its therapy.

RESUMEN

South America has a complex demographic history shaped by multiple migration and admixture events in pre- and post-colonial times. Settled over 14,000 years ago by Native Americans, South America has experienced migrations of European and African individuals, similar to other regions in the Americas. However, the timing and magnitude of these events resulted in markedly different patterns of admixture throughout Latin America. We use genome-wide SNP data for 437 admixed individuals from 5 countries (Colombia, Ecuador, Peru, Chile, and Argentina) to explore the population structure and demographic history of South American Latinos. We combined these data with population reference panels from Africa, Asia, Europe and the Americas to perform global ancestry analysis and infer the subcontinental origin of the European and Native American ancestry components of the admixed individuals. By applying ancestry-specific PCA analyses we find that most of the European ancestry in South American Latinos is from the Iberian Peninsula; however, many individuals trace their ancestry back to Italy, especially within Argentina. We find a strong gradient in the Native American ancestry component of South American Latinos associated with country of origin and the geography of local indigenous populations. For example, Native American genomic segments in Peruvians show greater affinities with Andean indigenous peoples like Quechua and Aymara, whereas Native American haplotypes from Colombians tend to cluster with Amazonian and coastal tribes from northern South America. Using ancestry tract length analysis we modeled post-colonial South American migration history as the youngest in Latin America during European colonization (9-14 generations ago), with an additional strong pulse of European migration occurring between 3 and 9 generations ago. These genetic footprints can impact our understanding of population-level differences in biomedical traits and, thus, inform future medical genetic studies in the region.

Asunto(s)